Digital Platform for Home-Based Sequential Therapy and Treatment of Glioma Including Recurrent Glioblastoma Using Propranolol or Imipramine Plus Bevacizumab

What this Trial Is About

Researchers are evaluating a digital platform that delivers home-based sequential therapy for patients with glioma, a type of brain tumor. This study aims to address the lack of specialized neuro-oncology care access in the United States, which affects survival outcomes. The trial also assesses the combination of propranolol or imipramine with bevacizumab for recurrent glioblastoma treatment, focusing on feasibility and effectiveness. Participants in this trial receive access to a remote chemotherapy management platform via a mobile app. They watch educational videos, report medication intake and side effects, and receive their standard chemotherapy as prescribed by their doctors. Those with recurrent glioblastoma may be randomly assigned to receive either propranolol or imipramine alongside bevacizumab, with treatment cycles repeating every 12 weeks if tolerated without disease progression. Imaging scans such as MRI or CT are done throughout the study. During the study, participants will be monitored remotely for treatment adherence and symptom reporting. They undergo scheduled imaging and clinical assessments to track tumor progression and response to therapy. Researchers measure outcomes including progression-free survival, overall survival, safety, patient satisfaction, and adherence for up to three years. Participants will be followed during treatment and may enter surveillance up to one year if no progression occurs.

A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial